Dr. Richard D'Amico becomes the first plastic surgeon in northern New Jersey to offer breakthrough HydraSolve™ liposuction treatment from Andrew Technologies
TUSTIN, Calif., Aug. 7, 2013 /PRNewswire/ -- Andrew Technologies announces the availability of the HydraSolve™ Lipoplasty System in northern New Jersey. Dr. Richard D'Amico www.drdamico.com at 180 N. Dean St, Suite 3-N in Englewood, N.J. has now purchased and accepted delivery of the area's first available HydraSolve™ Lipoplasty System.
HydraSolve™ is a novel liposuction device based on the same patented Tissue Liquefaction Technology™ that was launched in 2003 by Alcon as the AquaLase® Liquefaction Device, a modality on the Infiniti Vision System, for precision cataract surgery. HydraSolve™ combines natural saline solution with low levels of pressure and temperature, to liquefy only targeted fat tissue. Because fat tissue is liquefied, the cutting of fat by forceful thrusts of the cannula is no longer required. The specially designed HydraSolve™ cannula is manufactured with aperture edges that have a rounded radius of curvature that do not cut tissue. It is the energized saline stream, inside the cannula, that liquefies targeted fat tissue while preserving blood vessels, nerves and connective tissue integrity. HydraSolve™ achieves liquefaction of fat tissue by cell disaggregation, not by emulsification and the lysing of cell membranes.
Dr. Richard D'Amico is certified by the American Board of Plastic Surgery and was the 2008 President of the American Society of Plastic Surgeons, the largest association of plastic surgeons in the world. He is on the Board of Directors of the Society of Plastic Surgery Skin Care Specialists and the prestigious American Society for Aesthetic Plastic Surgery where he serves on the Innovative Technology Committee, which evaluates and makes recommendations on the latest procedures and techniques performed in cosmetic surgery. Dr. D'Amico earned his medical degree at the New York University School of Medicine and served his internship at Georgetown University and his surgical residency at University of Rochester. He completed his plastic surgery fellowship at Columbia Presbyterian Medical Center in New York City. He has been a board-certified plastic surgeon since 1986. Dr. D'Amico is a past-president of the New Jersey Society of Plastic Surgeons. He is a faculty member at Mt. Sinai School of Medicine, where he is the Assistant Clinical Professor of Plastic Surgery, and is Chief of the Department of Plastic Surgery at Englewood Hospital and Medical Center in Englewood, New Jersey.
Dr. Mark S. Andrew, Founder and Chief Scientific Officer of Andrew Technologies stated "we worked closely with Dr. D'Amico during the prototype testing phase of our research and development program. Due to his superb surgical skill and extensive liposuction experience, as well as his progressive and forward mindset, we gained extensive insight about the clinical capabilities of HydraSolve™. We are thrilled that Dr. D'Amico will be the first plastic surgeon in north Jersey to offer the benefits of HydraSolve™ to his patients." According to Dr. D'Amico, "From my clinical experience, I have found that HydraSolve™ is clearly more efficient and my opinion is that it is less traumatic and may result in less blood loss for a given amount of lipoaspirate. Therefore we are excited to offer HydraSolve for our patients seeking liposuction."
About Andrew Technologies, LLC
Andrew Technologies, founded in 2007, is a medical technology company committed to improving patients' lives through body aesthetics and pursuit of surgical applications of Tissue Liquefaction Technology. Andrew Technologies is a venture capital funded company based in Orange County, CA and Haddonfield, NJ. Our primary investors are WFD Ventures http://www.wfdventures.com/ and NJTC Venture Fund http://www.njtcvc.com/.
SOURCE Andrew Technologies